Products


PharmAthene was formed in March 2001 with a mission to become the premier company worldwide specializing in therapeutic and prophylactic products for defense against terrorist threats, with the opportunity for expansion into broader commercial applications. Since its inception, PharmAthene has pursued an acquisitive growth strategy focused on high priority biodefense products that the government has expressed a clear need and intent to procure. Currently, its portfolio includes five potential best-in-class biodefense medical countermeasures:


Pharmathene Overview

SparVax™ Fact Sheet

Valortim® Fact Sheet

Protexia® Fact Sheet

RypVax™ Fact Sheet

Recombinant Protective Antigen (rPA) Anthrax Vaccines Fact Sheet

Investor Fact Sheet